Key facts
- This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jul 2022, 19:06.
Eric Lefebvre - 11 Jul 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PLRX
- Reported as of
- 11 Jul 2022
- Net transaction value
- -$60,000
- SEC form
- 4
- Accepted by SEC
- 13 Jul 2022, 19:06:38 UTC
- Prior SEC filing
- 21 Mar 2022
- Next SEC filing
- 27 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 13 Jul 2022.
Change
- Previous filing in this sequence was filed on 21 Mar 2022.
- Current net transaction value: -$60,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Sale
- Transaction value
- $60,000
- Shares
- -3,000
- Change %
- -2.1%
- Price
- $20.00
- Shares after
- 138,436
- Date
- 11 Jul 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020.
Footnote F2
Includes 4,356 shares of Common Stock acquired by the reporting person pursuant to an employee stock purchase program.